Antibodies against GD2 ganglioside can eradicate syngeneic cancer micrometastases

Cancer Research

Volumn 58, Issue 13, 1998, Pages 2844-2849

  Zhang, Helen ^a   Zhang, Shengle ^a   Cheung, Nai Kong V ^a   Ragupathi, Govindaswami ^a   Livingston, Philip O ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; GANGLIOSIDE ANTIBODY; GANGLIOSIDE GD2; MEMBRANE ANTIGEN; MONOCLONAL ANTIBODY;

ADJUVANT THERAPY; ANIMAL CELL; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CANCER IMMUNIZATION; CANCER SURVIVAL; CELL LINE; LIVER METASTASIS; LYMPHOMA CELL; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, MONOCLONAL; CANCER VACCINES; GANGLIOSIDES; HEMOCYANIN; LIVER NEOPLASMS; LYMPHOMA; MICE; MICE, INBRED C57BL; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION;

EID: 0032127337     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Irie, R. F., Matsuki, T., and Morton, D. L. Human monoclonal antibody to ganglioside GM2 for melanoma treatment. Lancet, i: 786-787, 1989.
2. Irie, R. F., and Morton, D. L. Regression of cutaneous metastatic melanoma by intralesional injection with human monoclonal antibody to ganglioside GD2. Proc. Natl. Acad. Sci. USA, 83: 8694-8698, 1986.
3. Cheung, N. V., Medof, M. E., and Munn, D. Immunotherapy with GD2 specific monoclonal antibodies. Adv. Neuroblastoma Res., 2: 619-632, 1988.
4. Albertini, M. R., Hank, J. A., Schiller, J. H., Khorsand, M., Borchert, A. A., Gan, J., Bechhofer, R., Storer, B., Reisfeld, R. A., and Sondel, P. M. Phase IB trial of chimeric antidisialoganglioside antibody plus interleukin 2 for melanoma patients. Clin. Cancer Res., 3: 1277-1288, 1997.
5. Saleh, M. N., Khazaeli, M. B., Wheeler, R. H., Dropcho, E., Liu, T., Urist, M., Miller, D. M., Lawson, S., Dixon, P., Russell, C. H., and LoBuglio, A. R Phase I trial of the murine monoclonal anti-GD2 antibody 14G9a in metastatic melanoma. Cancer Res., 52: 4342-4347, 1992.
6. Dippold, W. G., Bernhard, H., Peter Dienes, H., and Meyer zum Buschenfelde, K-H. Treatment of patients with malignant melanoma by monoclonal ganglioside antibodies. Eur. J. Cancer Clin. Oncol., 24 (Suppl.): S65-S67, 1988.
7. Houghton, A. N., Mintzer, D., Cordon-Cardo, C., Welt, B., Fliegel, S., Vadhan, S., Carswell, E., Melamed, M. R., Oettgen, H. F., and Old, L. J. Mouse monoclonal antibody IgG3 antibody detecting GD3 ganglioside. A Phase I trial in patients with malignant melanoma. Proc. Natl. Acad. Sci. USA, 82: 1242-1246, 1985.
8. Raymond, J., Kirkwood, J., Vlock, D., Rabkin, M., Day, R., Whiteside, T., Herberman, R., Mascari, R., and Simon, B. A Phase IB trial of murine monoclonal antibody R24 (anti-GD3) in metastatic melanoma. Proc. Am. Soc. Clin. Oncol., 7: A958, 1988.
9. her2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J. Clin. Oncol., 41: 737-744, 1996.
10. Meeker, T. C., Lowder, J., Maloney, D. G., Miller, R. A., Thielemans, K., Warnke, R., and Levy, R. A clinical trial of anti-idiotype therapy for B cell malignancy. Blood, 65: 1349-1363, 1985.
11. Maloney, D. G., Levy, R., and Miller, R. A. Monoclonal anti-idiotype therapy of B cell lymphoma. Biol. Ther. Cancer Updates, 2: 1-10, 1992.
12. Frost, J. D., Hank, J. A., Reaman, G. H., Friedich, S., Seeger, R. C., Gan, J., Anderson, P. M., Ettinger, L. J., Cairo, M. S., Blazar, B. R., Krallo, M. D., Matthay, K. K., Reisfeld, R. A., and Sondel, P. M. A Phase I/IB trial of murine monoclonal anti-GD2 antibody. G2a plus interleukin-2 in children with refractory neuroblastoma. Cancer (Phila.), 80: 317-333, 1997.
13. 2 specific monoclonal antibody 3F8: A Phase I study in patients with neuroblastoma and malignant melanoma. J. Clin. Oncol., 5: 1430-1440, 1987.
14. Saleh, M. N., Khazaeli, M. B., Wheeler, R. H., Allen, L., Tilden, A. B., Grizzle, W., Reisfeld, R. A., Yu, A. L., Gillies, S. D., and LoBuglio, A. F. Phase I trial of the chimeric anti-GD2 monoclonal antibody ch14.18 in patients with malignant melanoma. Hum. Antib. Hybrid., 3: 19-24, 1992.
15. Pancook, J. D., Becker, J. C., Gillies, S. D., and Reisfeld, R. A. Eradication of established hepatic human neuroblastoma metastases in mice with severe combined immunodeficiency by antibody-targeted interleukin-2. Cancer Immunol. Immunother., 42: 88-92, 1996.
16. Eisenthal, A., Lafreniere, R. Lefor, A. T., and Rosenberg, S. A. Effect of anti-B16 melanoma monoclonal antibody on established murine B16 melanoma liver metastases. Cancer Res., 47: 2771-2776, 1987.
17. Hara, I., Takechi, Y., and Houghton, A. N. Implicating a role for immune recognition of self in tumor rejection: Passive immunization against the brown locus protein. J. Exp. Med., 182: 1609-1614, 1995.
18. Law, L. W., Vieira, W. D., Hearing, V. J., and Gersten, D. M. Further studies of the therapeutic effects of murine melanoma-specific monoclonal antibodies. Biochim. Biophys. Acta, 1226: 105-109, 1994.
19. Nagy, E., Berezi, I., and Sehon, A. H. Growth inhibition of murine mammary carcinoma by monoclonal IgE antibodies specific for the mammary tumor virus. Cancer Immunol. Immunother., 34: 63-69, 1991.
20. 3 ganglioside. Melanoma Res., 2 (Suppl.): S155-S162, 1997.
21. 3 gangliosides. J. Natl. Cancer Inst. (Bethesda), 6: 440-444, 1989.
22. D2 antibody 14.18. Cancer Res., 49: 2857-2861, 1989.
23. Darnell, R. B. Onconeural antigens and the paraneoplastic neurologic disorders: at the intersection of cancer, immunity, and the brain. Proc. Natl. Acad. Sci. USA, 93: 4529-4536, 1996.
24. Dalmau, J., Graus, F., Cheung, N-K. V., Rosenblum, M. K., Ho, A., Canete, A., Delattre, J-Y., Thompson, S. J., and Posner, J. B. Major histocompatibility proteins, anti-Hu antibodies, and paraneoplastic encephalomyelitis in neuroblastoma and small cell lung cancer. Cancer (Phila.), 75: 99-109, 1995.
25. Graus, F., Dalmau, J., Rene, R., Tora, M., Malats, N., Verschuuren, J. J., Cardenal, F., Vinolas, N., Garcia del Muro, J., Vadell, C., Mason, W. P., Resell, R., Posner, J. B., and Real, F. X. Anti-Hu antibodies in patients with small-cell lung cancer: association with complete response to therapy and improved survival. J Clin. Oncol., 15: 2866-2872, 1997.
26. Livingston, P. O., Wong, G. Y., Adluri, S., Tao, Y., Padavan, M., Parente, R., Hanlon, C., Calves, M. J., Helling, F., and Ritter, G. Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaocination with GM2 ganglioside. J. Clin. Oncol., 12: 1036-1044, 1994.
27. Jones, P. C., Sze, L. L., Liu, P. Y., Morton, D. L., and Irie, R. F. Prolonged survival for melanoma patients with elevated IgM antibody to oncofetal antigen. J. Natl. Cancer Inst. (Bethesda), 66: 249-254, 1981.
28. Winter, S. F., Sekido, Y., Minna, J. D., McIntire, D., Johnson, B. E., Gazdar, A. F., and Carbone, D. P. Antibodies against autologous tumor cell proteins in patients with small-cell lung cancer. Association with improved survival. J. Natl. Cancer Inst. (Bethesda), 85: 2012-2018, 1993.
29. Riethmuller, G., Schneider-Gadicke, E., Schlimok, G., Schmiegel, W., Raab, R., Hoffken, K., Gruber, R., Pichlmaier, H., Hirche, H., Pichlmayr, R., Buggisch, P., Witte, J., and the German Cancer Aid 17-Study Group. Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. Lancet, 343: 1177-1183, 1994.
30. Mittelman, A., Chen, G. Z. J., Wong, G. Y., Liu, C., Hirai, S., and Ferrone, S. Human high molecular weight-melanoma associated antigen mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: modulation of the immunogenicity in patients with malignant melanoma. Clin. Cancer Res., 1: 705-713, 1995.
31. Morton, D. L., Foshag, L. J., Hoon, D. S., Nizze, J. A., Famatiga, E., Wanek, L. A., Change, C., Davtyan, D. G., Gupta, R. K., and Elashoff, R. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine (Published erratum appears in Ann. Surg., 277: 309, 1993). Ann. Surg., 216: 463-482, 1992.
32. Miller, K., Abeles, G., Oratz, R., Zeleniuch-Jacquotte, A., Cui, J., Roses, D. F., Harris, M. N., and Bystryn, J. C. Improved survival of patients with melanoma with an antibody response to immunization to a polyvalent melanoma vaccine. Cancer (Phila.), 75: 495-502, 1995.
33. MacLean, G. D., Reddish, M. A., Koganty, R. R., and Longenecker, B. M. Antibodies against mucin-associated sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine. J. Immunother., 19: 59-68, 1996.
34. Zhao, X., and Cheung, N. V. GD2 oligosaccharide: target for cytotoxic T lymphocytes. J. Exp. Med., 182: 67-74, 1995.
35. Cheung, N-K., Saarinen, U. M., Neely, J. E., Landmeier, B., Donovan, D., and Coccia, P. F. Monoclonal antibody to a glycolipid antigen on human neuroblastoma cells. Cancer Res., 45: 2642-2649, 1985.
36. Shitara, K., Fujiwara, K., Igarashi, S., Ohta, S., Furuya, A., Nakamura, K., Koiki, M., and Hanai, N. Immunoglobulin class switch of anti-ganglioside monoclonal antibody from IgM to IgG. J. Immunol. Methods, 169: 83-92, 1994.
37. Dracopoli, N. C., Rettig, W. J., Albino, A. P., Esposito, D., Archidiacono, N., Rocchi, M., Siniscalco, M., and Old, L. J. Genes controlling gp25/30 cell surface molecules map to chromosomes X and Y and escape X-inactivation. Am. J. Hum. Genet., 37: 199-207, 1985.
38. Singhal, A., Fohn, M., and Hakomori, S-I. Induction of a-N-acetylgalactosamine-O-serine/threonine (Tn) antigen-mediated cellular immune response for active immunotherapy in mice. Cancer Res., 51: 1406-1411, 1991.
39. Kensil, C. R., Patel, U., Lennick, M., and Marciani, D. Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex. J. Immunol., 146: 431-437, 1991.
40. Helling, F., Shang, Y., Calves, M., Oettgen, H. F., and Livingston, P. O. Increased immunogenicity of 1D3 conjugate vaccines: comparison of various carrier proteins and selection of GD3-KLH for further testing. Cancer Res. 54: 197-203, 1994.
41. Zhang, S., Helling, F., Lloyd, K. O., and Livingston, P. O. Increased tumor cell reactivity and complement dependent cytotoxicity with mixtures of monoclonal antibodies against different gangliosides. Cancer Immunol. Immunother., 40: 88-94, 1995.
42. Huntsberger, D. V., and Leaverton, P. E. (eds.). Statistical Inference in the Biomedical Sciences, pp. 138-140, 337-338. Boston: Allyn and Bacon, 1970.
43. Raff, H. V., Bradley, C., Brady, W., Donaldson, K., Lipsich, L., Maloney, G., Shufford, W., Walls, M., Ward, P., Wolff, E., and Harris, L. J. Comparison of functional activities between IgG1 and IgM class-switched human monoclonal antibodies reactive with group B Streptococci orEscherichia coli K1. J. Infect. Dis., 163: 346-355, 1991.
44. Livingston, P. O., Ritter, G., Srivastava, P., Padavan, M., Calves, M. J. Oettgen, H. F., and Old, L. J. Characterization of IgG and IgM antibodies induced in melanoma patients by immunization with purified GM2 ganglioside. Cancer Res., 49: 7045-7050, 1989.
45. Livingston, P. O., Zhang, S., Walberg, L., Ragupathi, G., Helling, F., and Fleischer, M. Tumor cell reactivity mediated by IgM antibodies in sera from melanoma patients vaccinated with GM2-KLH is increased by IgG antibodies. Cancer Immunol. Immunother., 43: 324-330, 1997.
46. Helling, F., Zhang, A., Shang, A., Adluri, S., Calves, M., Koganty, R., Longenecker, B. M., Oettgen, H. F., and Livingston, P. O. GM2-KLH conjugate vaccine: increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21. Cancer Res., 55: 2783-2788, 1995.
47. Livingston, P. O. Approaches to augmenting the immunogenicity of melanoma gangliosides: from whole melanoma cells to ganglioside-KLH conjugate vaccines. Immunol. Rev., 145: 147-166, 1995.
48. Svennerholm, L. Chromatographic separation of human brain gangloisides. J. Neurochem., 10: 613-623, 1963.